Ads
related to: prostate vs prostatore in women treatment
Search results
Results from the WOW.Com Content Network
Flutamide (Eulexin): Marketed for the treatment of prostate cancer and also used in the treatment of acne, hirsutism, and hyperandrogenism in women. [3] [4] It has also been studied in the treatment of benign prostatic hyperplasia. [6] Now little-used due to high incidence of elevated liver enzymes and hepatotoxicity and the availability of ...
Used for androgen-dependent indications in women and transgender women, particularly in the United States where cyproterone acetate is unavailable. Studied in the treatment of benign prostatic hyperplasia but was found to be ineffective. Contraindicated in prostate cancer due to weak androgenic activity and stimulation of tumor growth.
Treatment is necessary only if symptoms negatively affect daily life and, according to the Mayo Clinic, include medications that help relax the muscles around the prostate and shrink the gland ...
Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. [1] Symptoms may include frequent urination , trouble starting to urinate, weak stream, inability to urinate , or loss of bladder control . [ 1 ]
Lowering androgen levels or stopping them from getting into prostate cancer cells often makes prostate cancer shrink or grow more slowly for a time. However, this treatment needs to be combined with radiation therapy (RT) [8] because ADT itself does not eradicate the cancer; it just decreases its aggressiveness. [9]
BPH can be treated with medication, a minimally invasive procedure or, in extreme cases, surgery that removes the prostate. In general, treatment often begins with an alpha-1 adrenergic receptor antagonist medication such as tamsulosin, which reduces the tone of the smooth muscle found in the urethra that passes through the prostate, making it ...
A 2015 Cochrane review found that NSAA monotherapy for prostate cancer had a greater risk of treatment discontinuation due to adverse effects than monotherapy with a GnRH agonist or surgical castration (RR = 1.82). [122] This included a greatly increased risk of breast pain (RR = 22.97) and gynecomastia (RR = 8.43). [122]
Treatments for bladder and prostate diseases depend on numerous factors including the specific condition diagnosed, the severity of the condition, and other individual characteristics. Treatments may be used in isolation or in combination with other treatments. [11] [8]
Ads
related to: prostate vs prostatore in women treatment